• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

5.850 UNCHANGED
Delayed Quote Updated: 4:00 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
Earnings to watch: Myriad Genetics (MYGN) reports Q3 results tomorrow
November 02, 2026
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be announcing earnings results this Wednesday afternoon. Here’s what to expect. Myriad Genetics mi... 
Via StockStory
News headline image
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
November 02, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
2 Russell 2000 stocks on our watchlist and 1 we ignore
October 29, 2026
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,... 
Via StockStory
News headline image
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
October 22, 2026
Data from ongoing study supports the potential clinical utility of whole-genome sequencing-based Precise MRD™ to identify recurrence risk and detect disease earlier following surgery 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Stocks making big moves yesterday: Washington Trust Bancorp, Doximity, Myriad Genetics, Arhaus, and Gartner
October 21, 2026
Check out the companies making headlines yesterday: Washington Trust Bancorp (NASDAQ:WASH): Regional bank Washington Trust Bancorp (NASDAQ:WASH) rose by 5% o... 
Via StockStory
Top US Stock Movers: Today's Session Gainers and Losers ↗
October 20, 2026
Via Chartmill
Top Movers: Gainers Rise 55.88%, Losers Fall 53.13% in Today's Session ↗
October 20, 2026
Via Chartmill
Gap Stocks: Gap-Up and Gap-Down Movers in Today's Session ↗
October 20, 2026
Via Chartmill
News headline image
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why
October 20, 2026
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 22.2% in the pre-market session after the company agreed to sell its Pr... 
Via StockStory
Topics Artificial Intelligence
News headline image
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
October 20, 2026
Transaction to benefit patients through expanded access and support Myriad’s strategic priorities 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
2 Small-Cap Stocks to Consider Right Now and 1 We Turn Down
October 19, 2026
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and... 
Via StockStory
News headline image
Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know
October 16, 2026
What Happened? A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp sell-offs as elevated bond yields r... 
Via StockStory
Topics Bonds Economy
News headline image
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
October 15, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Q2 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
October 14, 2026
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the biotechnology industry, including Regeneron (NASDAQ:REGN) and... 
Via StockStory
Topics Artificial Intelligence
News headline image
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
October 08, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)
October 07, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD)... 
Via StockStory
Topics Artificial Intelligence
News headline image
Why Is Myriad Genetics (MYGN) Stock Soaring Today
October 02, 2026
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 5% in the afternoon session after Craig-Hallum analyst John Wilkin rais... 
Via StockStory
News headline image
1 Volatile Stock on Our Buy List and 2 We Question
October 02, 2026
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be... 
Via StockStory
News headline image
3 Reasons MYGN is Risky and 1 Stock to Buy Instead
September 24, 2026
Over the past six months, Myriad Genetics’s stock price fell to $4.01. Shareholders have lost 13% of their capital, which is disappointing considering the S&... 
Via StockStory
Topics Bankruptcy
News headline image
Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)
September 21, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its pe... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Unpopular Stock That Deserves Some Love and 2 We Turn Down
September 17, 2026
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
News headline image
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
September 16, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
2 Unprofitable Stocks to Research Further and 1 We Find Risky
September 15, 2026
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
News headline image
Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks
September 09, 2026
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD... 
Via StockStory
Topics Artificial Intelligence
News headline image
Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)
September 07, 2026
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers. Over th... 
Via StockStory
Topics Artificial Intelligence
News headline image
Stocks making big moves yesterday: Myriad Genetics, Greenbrier, Tidewater, Strategy, and Charter
September 02, 2026
Check out the companies making headlines yesterday: Myriad Genetics (NASDAQ:MYGN): Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell by 6.2% on Tues... 
Via StockStory
Topics Economy
News headline image
Why Myriad Genetics (MYGN) Stock Is Down Today
September 01, 2026
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 6.2% in the afternoon session after Piper Sandler double-downgraded the s... 
Via StockStory
News headline image
Q2 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks
August 27, 2026
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Moderna (NASDAQ:MRNA) and its peers. Over the next f... 
Via StockStory
Topics Artificial Intelligence
News headline image
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
August 27, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics and Moderna Shares Plummet, What You Need To Know
August 24, 2026
What Happened? A number of stocks fell in the afternoon session after shares across biotech and big pharma cooled further as traders continued to secure prof... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap